Showing results (631-640 of 1,523) with videos related to

Sort By:
Pageof 153
CPT: Pharmacometrics & Systems Pharmacology|December 18, 2024
Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitisYuki Otani, Laiyi Chua, Wendy J Komocsar, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 27, 2024
QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid-Beta Exposure in Upregulating VCAM1 Expression at the BBB EndotheliumZengtao Wang, Vaishnavi Veerareddy, Xiaojiao Tang, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 3, 2025
Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsymJames J Beaudoin, Kyunghee Yang, Brett A Howell, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2025
Pyridoxic Acid as Endogenous Biomarker of Renal Organic Anion Transporter Activity: Population Variability and Mechanistic Modeling to Predict Drug-Drug InteractionsAarzoo Thakur, Sumathy Mathialagan, Emi Kimoto, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2025
Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AIMélanie Karlsen, Sonia Khier, David Fabre, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 15, 2025
Population exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areataYuchen Wang, Yeamin Huh, Alexandre Lejeune
CPT: Pharmacometrics & Systems Pharmacology|January 8, 2025
A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With PembrolizumabAkihiro Yamada, Mary P Choules, Frances A Brightman, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 20, 2025
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple SclerosisStefan P H van den Berg, Alyssa A Toorop, Femke Hooijberg, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2025
Genotype, Ethnicity, and Drug-Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin-I StoryYuki Ujihira, Shawn Pei Feng Tan, Daniel Scotcher, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2025
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid TumorsChengjun Jiang, Fang Ren, Mingfei Zhang, et al.
Pageof 153